Abstract: The present disclosure relates to a modified polypeptide having xylanase activity and use thereof.

Abstract: Disclosed is a modified polypeptide having mannanase activity and a use thereof.

Abstract: A cathode active material for a lithium secondary battery includes a lithium-transition metal oxide including nickel (Ni), cobalt (Co), manganese (Mn), strontium (Sr) and sulfur (S). A mole fraction of nickel based on the total number of moles of nickel, cobalt and manganese in the lithium-transition metal oxide is 0.9 or more. A molar ratio of cobalt relative to manganese in the lithium-transition metal oxide is in a range from 0.9 to 1.5. A molar ratio of strontium (Sr) relative to sulfur (S) in the lithium-transition metal oxide is greater than 0, and 4 or less.

Abstract: Provided are an anti-4-1BB/anti-HER2 bispecific antibody, and a pharmaceutical composition and a method for treating and/or preventing a cancer using the same.

Abstract: In a method for ameliorating or treating a respiratory disease, a composition including a Lysimachia mauritiana extract as effective component is administered to a subject in need thereof. Since the Lysimachia mauritiana extract is effective in reducing the production amount of the chemokine RANTES, an inflammatory mediator, from bronchial epithelial cells, which are respiratory cells, the composition can be advantageously used as a functional health food or medicine for respiratory diseases including asthma or chronic obstructive pulmonary disease (COPD).

Abstract: A composition for preventing, ameliorating or treating a respiratory disease includes fermented Centella asiatica extract as effective component. The composition is effective in, in bronchial epithelial cells as respiratory cells, reducing the production amount of the inflammatory chemokine RANTES, protecting damaged cells induced by LPS, and reducing the expression level of the inflammatory cytokine IL-6, and it can also reduce the neutrophil count and regulate the expression level of inflammatory cytokines or chemokines in an animal model of lung injury. Accordingly, it can be advantageously used for a functional health food for preventing or ameliorating a respiratory disease, or a pharmaceutical product for preventing or treating a respiratory disease.

Abstract: A composition for strengthening, developing, differentiating, or regenerating muscle, or preventing, ameliorating, or treating muscle loss or muscle fatigue includes a Schizonepeta tenuifolia extract as an effective component. The Schizonepeta tenuifolia extract as an effective component has the effects of restoring the viability of muscle cells, increasing the endurance time on the rotarod performance test, i.e., the holding time without falling off from the rod, compared to the control group, reducing the content of LDH, AST, and ALT in blood, increasing the grip strength, enhancing the expression amount of energy metabolism-related genes in muscle tissues, increasing the density of muscle fibers in muscle tissues, inducing a change in the fibroblast arrangement to have a well-organized structure, and reducing the expression of MuRF1 in muscle tissues, as compared to the control group.

Abstract: A method for or treating respiratory disease according to an embodiment includes administering to a subject in need thereof an extract of Siraitia grosvenorii residuals as an effective component. The extract of Siraitia grosvenorii residuals has, in an animal model having asthma induced by ovalbumin (OVA), an effect of reducing airway hyper-responsiveness, inhibiting inflammatory cells in bronchoalveolar lavage fluid (BALF), reducing Th2 cytokines (IL-4, IL-5, and IL-13) in BALF, reducing inflammation and tissue damage in lung tissues, inhibiting contraction of airway smooth muscle and airway inflammation, an effect of inhibiting expression of IL-13, TARC, TNF-?, IL-17, and MUC5AC, which is a gene encoding mucus protein, in lung tissues, an effect of reducing the level of ovalbumin-specific IgE in blood serum, and an effect of reducing ROS in alveolar cells which is generated in excess amount due to fine dust.

Abstract: A method for treating osteoarthritis according to an embodiment of the present invention includes administering to a subject in need thereof a composition comprising an extract of Alpinia oxyphylla. The extract of Alpinia oxyphylla can reduce the expression of IL-1?, IL-6, TNF-? and COX-2 as an inflammatory factor and also the expression of MMP-9 as a cartilage degeneration-inducing factor, and can heal the cartilage damage, and thus it can be advantageously used as a functional health food composition for prevention or improvement of osteoarthritis or a therapeutic agent for osteoarthritis.

Abstract: The present invention relates to a composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising an extract of Alpinia oxyphylla as an effective ingredient. Because the extract of Alpinia oxyphylla of the present invention can reduce the uric acid amount in blood of an animal model and is derived from natural products, and the raw materials can be easily obtained, it can be widely used in industries that are related to hyperuricemia or metabolic disorders related with hyperuricemia. It can be effectively used for prevention, amelioration, or treatment of gout or gouty arthritis, in particular.

Abstract: The present invention relates to a composition for preventing, ameliorating, or treating hyperuricemia or metabolic disorders related with hyperuricemia comprising an extract of Alpinia oxyphylla as an effective ingredient. Because the extract of Alpinia oxyphylla of the present invention can reduce the uric acid amount in blood of an animal model and is derived from natural products, and the raw materials can be easily obtained, it can be widely used in industries that are related to hyperuricemia or metabolic disorders related with hyperuricemia. It can be effectively used for prevention, amelioration, or treatment of gout or gouty arthritis, in particular.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotriene, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatment of atopic dermatitis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermatitis.

Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

Abstract: The present invention relates to a novel compound with thiazole ring having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotrien, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatment of atopic dermatitis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermatitis.

Abstract: The present invention relates to a composition comprising of plant extract as an active component, specifically, Bamboo extract and Scutellaria extract, for the treatment and prevention of atopic dermatitis. The present invention is a natural ingredient obtained from a plant. The present invention can control immune responses by inhibiting the release of histamine and leukotrien, and thus, has effect in the treatment or prevention of allergic diseases, inflammatory diseases and skin diseases, specifically atopic dermatitis. The present invention has been proven safe and beneficial effecting the treatment of atopic dermatitis through clinical trials, and thus, can be used for the treatment and prevention of atopic dermatitis.

Abstract: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.

Abstract: A novel C-aryl glucoside compound, or a pharmaceutically acceptable salt or a prodrug thereof having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney; and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly, diabetes, are provided.

Abstract: The present invention is directed to a novel prodrug of (+)-3-hydroxymorphinan compound of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing the same, and its use for preventing or treating Parkinson's disease.